Hematopoietic Stem Cell TransplantationStem CellsStem Cell TransplantationTransplantation, HomologousTransplantation, AutologousHematologic NeoplasmsHematopoietic Stem CellsTransplantationGraft vs Host DiseaseEmbryonic Stem CellsTransplantation ConditioningAdult Stem CellsImmunocompromised HostCytomegalovirus InfectionsPeripheral Blood Stem Cell TransplantationTissue DonorsPluripotent Stem CellsTreatment OutcomeBone Marrow TransplantationGraft SurvivalOpportunistic InfectionsStem Cell NicheMycosesKidney TransplantationRetrospective StudiesHistocompatibility TestingImmunosuppressive AgentsAspergillosisNeural Stem CellsInduced Pluripotent Stem CellsCell DifferentiationMesenchymal Stem Cell TransplantationRoseolovirus InfectionsHematopoietic Stem Cell MobilizationTransplantsHistocompatibilityTime FactorsMultipotent Stem CellsCytomegalovirusRecurrenceLeukemiaMesenchymal Stromal CellsStem Cell FactorMultiple MyelomaGraft RejectionWhole-Body IrradiationHematologic DiseasesAntifungal AgentsNeoplasmsAntiviral AgentsBusulfanFatal OutcomeTransplantation ChimeraCombined Modality TherapyAntigens, CD34Cord Blood Stem Cell TransplantationHepatic Veno-Occlusive DiseaseCell LineageSurvival RateHerpesvirus 6, HumanCells, CulturedSurvival AnalysisGanciclovirRisk FactorsSalvage TherapyBK VirusZygomycosisFlow CytometryStem Cell ResearchFollow-Up StudiesPolyomavirus InfectionsAnemia, AplasticLymphoproliferative DisordersCyclosporineCell ProliferationPlant StemsAcute DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAntineoplastic Combined Chemotherapy ProtocolsImmunosuppressionFetal Stem CellsLeukemia, Myeloid, AcuteAntineoplastic AgentsProspective StudiesIncidenceBone Marrow CellsHeart TransplantationNeutropeniaTriazolesMyeloablative AgonistsPostoperative ComplicationsVirus ActivationChimerismPrognosisLymphoma, Non-HodgkinNeoplastic Stem CellsEpstein-Barr Virus InfectionsPolymerase Chain ReactionPyrimidines